Atty Dkt No. PP0926.105 USSN: 09/558,741 PATENT

AMENDMENT

In the Specification:

On page 16, line 30, after "SEQ ID NOS.: 1 and 2." please insert the following:

--The CDRs of the 520C9 antibody are set forth in the Sequence Listing as amino acid residue numbers 31 through 35, 50 through 66, 99 through 104, 157 through 167, 183 through 189, and 222 through 230 in SEQ ID NOs 5 and 6.--

On page 18, line 12, after "fragments." please insert the following:

--The single chain Fv and sFv fusion proteins of this invention offer fewer cleavage sites to circulating proteolytic enzymes and thus offer greater stability. They reach their target tissue more rapidly, and are cleared more quickly from the body, which makes them ideal imaging agents for tumor detection and ideal radioimmunotherapeutic agents for tumor killing. They also have reduced non-specific binding and immunogenicity relative to murine immunoglobins.--

TECH CENTER 1622 233

On page 46, line 19, after "linker." please insert the following:

--The gene contains nucleic acid sequences encoding V_H and V_L regions of the 520C9 antibody described above linked together with a double-stranded synthetic oligonucleotide coding for a peptide with the amino acid sequence set forth in the Sequence Listing as amino acid residue numbers 116-133 in SEQ ID NOs: 5 and 6.--

In the Claims:

Please cancel claims 1, 34-36, 44, and 48, without prejudice or disclaimer, and amend claims 33, 34, and 42, as follows: